{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:09:09Z","timestamp":1792346949868,"version":"4.4.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Dev Behav Pediatr"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To assess the efficacy of the non-stimulant guanfacine extended release (GXR) on attention-deficit\/hyperactivity disorder (ADHD) symptoms in children and adolescents, with and without comorbid oppositional defiant disorder (ODD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data were derived from 4 phase 3, randomized, placebo-controlled trials of dose-optimized GXR monotherapy, in which at least 10% of participants had a diagnosis of comorbid ODD. SPD503-312 and SPD503-316 were 10- to 13-week studies of GXR (1\u20137 mg\/d). SPD503-314 and SPD503-307 were 8-week studies of GXR (1\u20134 mg\/d). Efficacy was assessed using the ADHD Rating Scale IV (ADHD-RS-IV) total scores.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 1,084 participants were included (SPD503-312 and SPD503-316, n = 537; SPD503-314, n = 333; and SPD503-307, n = 214). GXR was associated with significant improvements in ADHD core symptoms at endpoint in participants with and without ODD (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01 in all studies). Placebo-adjusted least-squares mean (95% confidence interval) changes from baseline to endpoint in the ADHD-RS-IV total scores in participants with and without ODD were \u22128.6 (\u221214.4, \u22122.8) and \u22127.3 (\u22129.5, \u22125.0) in the pooled data from SPD503-312 and SPD503-316, \u221212.6 (\u221219.6, \u22125.7) and \u22128.7 (\u221211.8, \u22125.5) in SPD503-314, and \u221212.7 (\u221217.3, \u22128.1) and \u221211.8 (\u221219.3, \u22124.4) in SPD503-307, respectively. The corresponding effect sizes were 0.688 and 0.598 in SPD503-312 and SPD503-316, 0.876 and 0.729 in SPD503-314, and 0.962 and 0.842 in SPD503-307.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The findings demonstrate the efficacy of GXR for treating ADHD in children and adolescents with comorbid ODD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dbp.0000000000000822","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:15:01Z","timestamp":1590009301000},"page":"565-570","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder"],"prefix":"10.1097","volume":"41","author":[{"given":"Jeffrey H.","family":"Newcorn","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Huss","sequence":"additional","affiliation":[{"name":"Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz, Mainz, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Connor","sequence":"additional","affiliation":[{"name":"Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Herv\u00e1s","sequence":"additional","affiliation":[{"name":"Psiquiatr\u00eda Infantil y Juvenil, University Hospital M\u00fatua de Terrassa, Barcelona, Spain;"},{"name":"IGAIN (Instituto Global de Atenci\u00f3n Integral al Neurodesarrollo), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Werner-Kiechle","sequence":"additional","affiliation":[{"name":"Shire, Zug, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Robertson","sequence":"additional","affiliation":[{"name":"Shire, Lexington, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/DBP.0b013e3181e121bd","article-title":"A review of attention-deficit\/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder","volume":"31","author":"Connor","year":"2010","journal-title":"J Dev Behav Pediatr."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40272-015-0143-3","article-title":"Pharmacological management of pediatric patients with comorbid attention-deficit hyperactivity disorder oppositional defiant disorder","volume":"17","author":"Connor","year":"2015","journal-title":"Paediatr Drugs"},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/1087054707308486","article-title":"ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptive behavior disorders?","volume":"12","author":"Connor","year":"2008","journal-title":"J Atten Disord."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1469-7610.2005.00422.x","article-title":"Developmental transitions among affective and behavioral disorders in adolescent boys","volume":"46","author":"Burke","year":"2005","journal-title":"J Child Psychol Psychiatry."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"e20160430","DOI":"10.1542\/peds.2016-0430","article-title":"Patterns of comorbidity among girls with ADHD: a meta-analysis","volume":"138","author":"Tung","year":"2016","journal-title":"Pediatrics"},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/chi.0b013e318033ff59","article-title":"A 30-year prospective follow-up study of hyperactive boys with conduct problems: adult criminality","volume":"46","author":"Satterfield","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1586\/ern.12.119","article-title":"Prevention of serious conduct problems in youth with attention deficit\/hyperactivity disorder","volume":"12","author":"Villodas","year":"2012","journal-title":"Expert Rev Neurother."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/070674371506000202","article-title":"The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine","volume":"60","author":"Pringsheim","year":"2015","journal-title":"Can J Psychiatry."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-015-0336-0","article-title":"Guanfacine extended release: a new pharmacological treatment option in europe","volume":"36","author":"Huss","year":"2016","journal-title":"Clin Drug Investig."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/108705470400800202","article-title":"Efficacy and safety of atomoxetine in childhood attention-deficit\/hyperactivity disorder with comorbid oppositional defiant disorder","volume":"8","author":"Kaplan","year":"2004","journal-title":"J Atten Disord."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004583-200503000-00008","article-title":"Atomoxetine treatment in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder","volume":"44","author":"Newcorn","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00213-006-0565-2","article-title":"Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data","volume":"190","author":"Biederman","year":"2007","journal-title":"Psychopharmacology (Berl)."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00213-007-0840-x","article-title":"Efficacy and safety of atomoxetine for attention-deficit\/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis","volume":"194","author":"Cheng","year":"2007","journal-title":"Psychopharmacology (Berl)."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaac.2013.06.006","article-title":"Randomized, double-blind trial of guanfacine extended release in children with attention-deficit\/hyperactivity disorder: morning or evening administration","volume":"52","author":"Newcorn","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40263-015-0291-6","article-title":"Does guanfacine extended release impact functional impairment in children with attention-deficit\/hyperactivity disorder? Results from a randomized controlled trial","volume":"29","author":"Stein","year":"2015","journal-title":"CNS Drugs"},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/cap.2013.0134","article-title":"Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form","volume":"24","author":"Young","year":"2014","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R22-20230908","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Connor","year":"2010","journal-title":"CNS Drugs"},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jaac.2015.08.016","article-title":"A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit\/hyperactivity disorder","volume":"54","author":"Wilens","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.euroneuro.2014.09.014","article-title":"Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, controlled, phase III trial","volume":"24","author":"Hervas","year":"2014","journal-title":"Eur Neuropsychopharmacol."},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","article-title":"Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data","volume":"36","author":"Kaufman","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R26-20230908","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10802-016-0170-8","article-title":"Sex differences in the prevalence of oppositional defiant disorder during middle childhood: a meta-analysis","volume":"45","author":"Demmer","year":"2017","journal-title":"J Abnorm Child Psychol."},{"key":"R27-20230908","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaac.2018.07.910","article-title":"Sex differences in comorbidity patterns of attention-deficit\/hyperactivity disorder","volume":"58","author":"Ottosen","year":"2019","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R28-20230908","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00004583-200203000-00004","article-title":"Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt\/covert aggression-related behaviors in ADHD","volume":"41","author":"Connor","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry."}],"container-title":["Journal of Developmental &amp; Behavioral Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:17:04Z","timestamp":1694157424000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/dbp.0000000000000822","relation":{},"ISSN":["0196-206X"],"issn-type":[{"value":"0196-206X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}